12:00 AM
 | 
Oct 15, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Prevnar 13: Additional Phase III data

Additional data from 900 healthy adults aged 18-49 in the open-label portion of the Phase III Study 004 trial showed that Prevnar 13 produced immune responses for all 13 serotypes contained in the vaccine that were non-inferior to the immune response produced in patients aged 60-64 in the double-blind portion of the trial. Pfizer said the data were included in a regulatory submission in the EU seeking to expand the label of Prevnar 13 to include use in adults aged 18-49. The trial comprised a double-blind...

Read the full 407 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >